ReviewOpen Access

Evidence of Autoimmune-Related Effects of Trichloroethylene Exposure from Studies in Mice and Humans

    Published: by:103



    Our objective was to examine experimental and epidemiologic studies pertaining to immune-related, and specifically autoimmune-related, effects of trichloroethylene (TCE).

    Data sources and extraction

    We performed a literature search of PubMed and reviewed bibliographies in identified articles. We then systematically reviewed immune-related data, focusing on clinical and immunologic features and mechanistic studies.

    Data synthesis

    Studies conducted in MRL+/+ lupus mice report an accelerated autoimmune response in relation to exposure to TCE or some metabolites. Effects have been reported after 4 weeks of exposure to TCE at doses as low as 0.1 mg/kg/day in drinking water and have included increased antinuclear antibodies and interferon-γ (IFN-γ) and decreased secretion of interleukin-4 (IL-4), consistent with an inflammatory response. Autoimmune hepatitis, inflammatory skin lesions, and alopecia have been found after exposures of 32–48 weeks. Recent mechanistic experiments in mice examined oxidative stress and, specifically, effects on lipid-peroxidation–derived aldehydes in TCE-induced autoimmune disease. Two studies in humans reported an increase in IL-2 or IFN-γ and a decrease in IL-4 in relation to occupational or environmental TCE exposure. Occupational exposure to TCE has also been associated with a severe, generalized hypersensitivity skin disorder accompanied by systemic effects, including hepatitis. In three case–control studies of scleroderma with a measure of occupational TCE exposure, the combined odds ratio was 2.5 [95% confidence interval (CI), 1.1–5.4] in men and 1.2 (95% CI, 0.58–2.6) in women.


    The consistency among the studies and the concordance between the studies in mice and humans support an etiologic role of TCE in autoimmune disease. Multisite collaborations and studies of preclinical immune markers are needed to further develop this field of research.

    Trichloroethylene (TCE) is an industrial solvent that has been used extensively in industrial operations involving metal cleaning and degreasing. Its metabolism through a cytochrome P450 (CYP) pathway involving the enzyme CYP2E1 results in numerous metabolites, including chloral, chloral hydrate, dichloroacetic acid, trichloracetic acid, trichloroethanol, and trichloroethanol glucuronide (Lash et al. 2000). Many studies of immune-related effects of TCE have been conducted in the past decade, with much of this work focusing on autoimmune disease. We reviewed this recent research to determine the strength and consistency of data from experimental and epidemiologic studies, and the concordance between human and animal data, pertaining to these effects.

    Materials and Methods

    We searched PubMed (National Center for Biotechnology Information 2008) for studies related to TCE and immune effects, using forms of “immune,” “autoimmune,” “immunosuppression,” “cytokines,” “lupus,” “scleroderma,” “rheumatoid arthritis,” “vasculitis,” and “liver” as search terms. We also reviewed references within relevant reports, including the National Academy of Sciences 2006 report on TCE (National Research Council 2006). We did not include studies of in utero or developmental exposures (Blossom and Doss 2007; Blossom et al. 2007; Peden-Adams et al. 2006, 2008) in this review.

    We abstracted data pertaining to immunosuppression, hypersensitivity, and autoimmune-related effects, including clinically expressed or clinically diagnosed disease, cytokine expression or levels, T-cell activation, and serology [antinuclear antibodies (ANA) and specific autoantibodies]. We present, in tabular form, end points that all, or almost all, of the identified reports examined and include information on both “positive” and “negative” effects found in the studies.

    We identified three case–control studies of scleroderma (systemic sclerosis) risk that included a specific assessment of occupational exposure to TCE in addition to more general assessments of “solvent” or “organic solvent” exposure (Diot et al. 2002; Garabrant et al. 2003; Nietert et al. 1998). We created graphical displays of the estimated measures of association from these studies using Comprehensive Meta Analysis, version 2.2.046 (Biostat, Inc., Englewood, NJ). We conducted a meta-analysis of these studies using a random-effects model to include the possibility of nonrandom error between studies (DerSimonian and Laird 1986). Studies were too sparse to do sensitivity analyses or explore sources of heterogeneity or potential publication bias.


    Immunosuppression Studies

    Several animal studies have examined immunosuppression and host resistance in relation to TCE exposures by various routes and concentrations of exposure. CD1 mice exhibited an increase in susceptibility to infectious agents (e.g., Streptococcus zooepidimicus, Klebsiella pneumoniae) with short-term (3-hr) inhalation TCE exposures ranging from 2.6 to 48 ppm (Aranyi et al. 1986). Another study in female CD1 mice provided evidence of decreased humoral immunity with oral exposure (via drinking water) to TCE at concentrations of 0.1, 1, 2.5, or 5 mg/mL for 3–6 months (Sanders et al. 1982). Kauffmann et al. (1982) found similar results in a study of male and female CD1 mice exposed to a TCE metabolite, chloral hydrate, at concentrations of 0.07 and 0.7 mg/mL. After 3 days of single intra peritoneal (ip) injections of TCE in Sprague-Dawley rats at 0.05, 0.5, or 5 mmol/kg/day and B6C3F1 mice at 10 mmol/kg/day, natural killer cell activity in the liver, but not the spleen, was depressed in rats given the highest dose (22% lower than control levels, p < 0.05); in mice, a smaller decrease was reported (14% lower than control levels), which was not statistically significant (Wright et al. 1991).

    Data pertaining to measures of immunosuppression (e.g., infectious disease risk) in humans are very limited. In 1979, testing of wells in Woburn, Massachusetts, revealed that the water in two of the wells was contaminated with a number of solvents, including TCE (267 ppb) (Lagakos et al. 1986). In 1982, Lagakos et al. (1986) used a telephone survey of Woburn residents (representing ~ 57% of the town residences with listed telephone numbers) to collect information on residential history and history of 14 types of medically diagnosed conditions for 4,978 children born since 1960 who lived in Woburn before they reached 19 years of age. Using exposure information based on estimates of the contribution of water from the contaminated wells in various zones within the town, Lagakos et al. (1986) estimated a cumulative exposure based on each child’s length of residence in Woburn. They found that a higher cumulative exposure measure was associated with a history of kidney and urinary tract disorders (primarily kidney or urinary tract infections) and with lung and respiratory disorders (asthma, chronic bronchitis, or pneumonia).

    Studies of Generalized Hypersensitivity Skin Diseases with Other Systemic Effects

    Occupational exposure to TCE has been associated with a severe, generalized skin disorder that is distinct from contact dermatitis in its clinical presentation (which often involves mucosal lesions) and in the accompanying systemic effects, which can include lymphadenopathy, hepatitis, and other organ involvement. In two studies investigating delayed hypersensitivity using the guinea pig maximization test, sensitization rates of 66–71% and skin edema and erythema were observed (Tang et al. 2002, 2008). Elevations in liver enzymes and presence of liver lesions were also reported by Tang et al. (2008). In the guinea pig maximization test they found histopathologic evidence of fatty degeneration in the liver, hepatic sinusoid dilation, and inflammatory cell infiltration with an acute intradermal dose of 4,500 mg/kg, and diffuse ballooning without lymphocytic infiltration or necrotic hepatocytes with a total dosage of ≤ 340 mg/kg.

    Kamijima et al. (2007) reviewed case reports describing 260 patients, mostly from Asia, with TCE-related generalized skin disorders. Their review is based on 26 articles published between 1966 and 2005 describing cases seen in China, Korea, Japan, Philippines, Singapore, Thailand, Spain, and the United States. One study in Guandong province, in southeastern China, included > 100 cases in a single year (Huang et al. 2002). Kamijima et al. (2007) categorized case descriptions as indicative of hypersensitivity syndrome (n = 124) or a variation of erythema multiforme, Stevens-Johnson syndrome, and toxic epiderma necrolysis (n = 115), with 21 other cases unclassified in either category. Hepatitis was common (> 50%), and the fatality rate (~ 10%) was similar in the two groups. Based on the reports reviewed by Kamijima et al. (2007), generalized skin disease within a work-site occurred in 0.25–13% of workers in the same location performing the same type of work. The measured concentration of TCE ranged from < 50 mg/m3 to > 4,000 mg/m3, and exposure scenarios included inhalation only and inhalation with dermal exposures. Disease manifestation generally occurred within 2–5 weeks of initial exposure, with some intervals of up to 3 months. Most of the reports were published after 1995, and the geographic distribution of cases reflects the newly industrializing areas within Asia. An analysis of breathing zone concentrations of volatile organochlorines and metal contaminants of the solvents used in factories of 25 workers hospitalized for hyper sensitivity skin disease and at similar factories with no affected workers in the past 3 years indicated no commonality of additives or impurities detected among the affected factories that could explain the occurrence of the hypersensitivity disorder (Kamijima et al. 2008).

    Autoimmune Disease Studies

    Autoimmune mouse models
    Acceleration of autoimmune response

    Several mouse strains spontaneously develop conditions resembling systemic lupus erythematosus seen in humans. These strains have been extensively used in mechanistic research pertaining to disease pathogenesis. The MRL-lpr and NZB × NZW mouse strains exhibit extremely high disease penetrance and early death. The MRL+/+ strain is less severely affected, with disease development after 12 months (compared with 6–8 months in MRL-lpr and female NZB × NZW mice) and a relatively low prevalence of renal involvement. The MRL+/+ mouse has been used most often in experimental studies of TCE exposure (Table 1).

    Table 1 Studies of TCE and metabolite effectsa in lupus mouse strains by strain, exposure route, and duration.

    Strain, reference(s), exposureSerologyStudies of cultured splenocytesClinical/histopathology results
    Female MRL+/+ mice, drinking water

    Gilbert et al. 1999; Griffin et al. 2000a  No. per group; 0, 2.5, 5 mg/mL TCE (average 0, 455, 734 mg/kg-day) for 4, 8, or 22 weeksIncreased ANA at 4 and 8 weeks; no difference between groups at 22 weeksIncreased activated CD4+ T cells and IFN-γ secretion across doses at 4 weeks, with effects reversed at 22 weeks; decreased IL-4 secretion (4 and 22 weeks)No evidence of liver or renal damage, based on serum alanine aminotransferase, sorbitol dehydrogenase, and blood urea nitrogen
    Griffin et al. 2000c 8 per group; 0, 0.1, 0.5, or 2.5 mg/mL TCE (0, 21, 100, or 400 mg/kg-day) for4 or 32 weeksIncreased ANA in all treated groups at 4 weeks but not at 32 weeksIncreased activated CD4+ T cells (32 weeks) and IFN-γ secretion (4 and 32 weeks); no effect on IL-4 secretionExtensive hepatic mononuclear cellular infiltrate in 0.5 and 2.5 mg/mL groups; hepatocyte reactive changes in all treated groups at 32 weeks
    Blossom et al. 2004 6–8 per group; 0, 0.1, 0.9 mg/mL trichloroacetaldehyde hydrate (0, 24, 220 mg/kg) or trichloroacetic acid (0, 27, 205 mg/kg-day) for 4 weeksIncreased ANA and anti-histone antibodies at 0.9 mg/mL trichloroacetaldehyde hydratebIncreased activated CD4+ T cells at 0.1 and 0.9 g/mL doses of both metabolites; increased IFN-γ secretion at 0.9 mg/mL; no effect on IL-4 secretionNo evidence of liver or kidney damage, based on serum alanine aminotransferase and liver and kidney histology
    Blossom et al. 2007 8 per group, 0, 0.1, 0.3, 0.9 mg/mL trichloroacetaldehyde hydrate (0, 13, 46, 143 mg/kg-day) for 40 weeksSlightly suppressed anti-ssDNA, anti-dsDNA, and anti-histone antibody expression; differences not statistically significantIncreased activated CD4+ T-cells and increased IFN-γ secretion; no effect on IL-4 secretionDiffuse alopecia, skin inflammation and ulceration, mononuclear cell infiltration, mast cell hyperplasia, and dermal fibrosis; statistically significant increase at 0.9 mg/mL dose group but also increased at lower doses; no liver or kidney histopathology effects seen
    Cai et al. 2008 5 per group, 0 or 0.5 mg/mL TCE (mean 60 μg/g-day) for 48 weeksIncreased ANA after 24 weeks but not statistically significantIncreased IFN-γ secretion after 36 weeks but not statistically significantHepatic necrosis; hepatocyte proliferation; leukocyte infiltrate in the liver, lungs, and kidneys; no difference in serum aminotransferase liver enzymes

    Female MRL+/+ mice, ip injection

    Khan et al. 1995 4–5 per group, in corn oil, 0 (corn oil), 10 mmol/kg TCE, 0.2 mmol/kg dichloroacetyl chloride, every 4th day for 6 weeksIn both groups, increased ANA and anti-ssDNA antibodies; in dichloroacetyl chloride group, anticardiolipin antibodies; no difference in anti-histone, -Sm, or -DNA antibodiesNot evaluatedNot evaluated
    Cai et al. 2006 6 per group, in corn oil, 0 (corn oil), 0.2 mmol/kg dichloroacetyl chloride, 0.2 mmol/kg dichloroacetic anhydride, twice per week for 6 weeksIn both treated groups, increased ANAIn both treated groups, increased IL-1α, IL-1β, IL-3, IL-6, IFN-γ, granulocyte colony–stimulating factor, and keratinocyte-derived chemokine secretion and decreased IL-5; in dichloroacetyl chloride group, increased IL-17 and IFN-αcIn both treated groups, increased lymphocytes in spleen and thickening of alveolar septa with lymphocytic interstitial infiltration

    Female NZB × NZW mice, drinking water

    Gilkeson et al. 2004 6 per group, 0, 1,400, or 14,000 ppb,d 26 weeks exposure; observed up to 36 weeksIncreased anti-dsDNA antibodies at some periods at ≥ 1,000 ppbNot evaluatedAt 10,000 ppb, proteinuria increased beginning at 20 weeks; renal pathology scores increased; no signs of liver disease

    Male MRL –lpr/lpr, inhalation

    Kaneko et al. 2000 5 per group, 0, 500, 1,000, 2,000 ppm TCE, 4 hr/day, 6 days/week for 8 weeksNot evaluatedNot evaluatedAt ≥ 500 ppm, dose-related liver inflammation, splenomegaly, and hyperplasia of lymphatic follicles; at 1,000 ppm, immunoblastic cell formation in lymphatic follicles; no changes in thymus

    ssDNA, single-strand DNA.

    aSelected end points based on those reported across most studies.

    bNo difference reported in anti-dsDNA, anti-ss-DNA, anti-ribonucleosome, anti-SSA, anti-SSB, anti-Sm, anti-Jo-1, or anti-Scl-70 antibodies.

    cNo difference in secretion of other cytokines measured: IL-2, IL-4, IL-10, IL-12, TNF-α, granulocyte monocyte colony–stimulating factor, macrophage inflammatory protein-1α, and RANTES (CCL-5).

    dDose not given in mg/kg-day. Dose levels cited by Gilkeson et al. (2004) were incorrectly reported as 1,000 and 10,000 ppb; corrected doses (Peden-Adams MM, personal communication) are reported here.

    Several studies in MRL+/+ mice reported autoimmune-related effects from exposure to TCE via drinking water (Blossom et al. 2004, 2007; Cai et al. 2008; Gilbert et al. 1999; Griffin et al. 2000a, 2000b, 2000c; Wang et al. 2007b) or ip injection (Cai et al. 2006; Khan et al. 1995) (Table 1). The initial drinking water study used relatively high TCE concentrations of 2.5 and 5 mg/mL, with serologic measurements of ANA and IgG levels and assays of activation of CD4+ T cells from splenocytes (Gilbert et al. 1999; Griffin et al. 2000a). Another study examined lower exposure levels (0.1, 0.5, and 2.5 mg/mL) and extended the observation to 32 weeks (Griffin et al. 2000b). These studies demonstrated an acceleration of the autoimmune response. T-cell activation peaked at 4–8 weeks in the higher-dose experiment and at 32 weeks in the lower-dose experiment. The higher dose study showed evidence of a reversal in effects at 22 weeks, with lower levels of CD4+ T-cell expression and interferon-γ (IFN-γ) in exposed mice compared with controls. The effects observed by Griffin et al. (2000a) with respect to formation of TCE–protein adducts and CD4+ T-cell activation were blocked in a parallel study of 2.5 mg/mL TCE via drinking water in which the CYP2E1 metabolic pathway was inhibited by the addition of dial-lyl sulfide (Griffin et al. 2000c). In another longer-exposure duration study using one dose group (0.5 mg/mL TCE in drinking water), Cai et al. (2008) found no evidence of systemic inflammation as determined by serum cytokines measured after 36–48 weeks of exposure: levels of two proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), were decreased, but there was no difference in IL-1α.

    Several studies demonstrated the involvement of one or more potential metabolites of TCE in the autoimmune response seen in MRL+/+ mice. These include studies of dichloroacetyl chloride (Khan et al. 1995, 2001), trichloroacetaldehyde hydrate (Blossom et al. 2004, 2007), and trichloroacetic acid (Blossom et al. 2004) (Table 1). Effects were similar to those found with TCE in terms of accelerated autoantibody expression, T-cell activation, and secretion of inflammatory cytokines, but some differences in clinical expression were found in the long-term studies. B-cell activation has not been observed in studies using TCE (Griffin et al. 2000a) or its metabolites (Blossom et al. 2004).

    Chronic effects

    The three chronic oral exposure studies in the MRL+/+ mouse, with exposure periods of 32–48 weeks, reported the presence of distinct clinical effects in exposed mice (Table 1). One of these effects was characterized as an auto immune hepatitis (Cai et al. 2008; Griffin et al. 2000b). Griffin et al. (2000b) found an inflammatory hepatic infiltrate in the portal tracts and lobular focal areas in the 0.5- and 2.5-mg/mL groups, with a dose-related effect on severity scores seen at 32 weeks. Alanine aminotransferase was also increased in the 0.5 mg/mL TCE dose group (means, 38.2 and 20.0 IU/L for 0.5 mg/mL and control groups, respectively). Cai et al. (2008) found similar liver lymphocytic infiltrates at 36 weeks and 48 weeks in a study using 0.5 mg/mL TCE exposure in drinking water, and infiltrates in the pancreas, lungs, and kidneys at 48 weeks. In a 40-week study using trichloroacetaldehyde hydrate, Blossom et al. (2007) found clinical effects, including diffuse alopecia and skin inflammation and ulceration, with increasing incidence across the dose groups; the difference between the 0.9 mg/mL group and the controls was statistically significant. Histologic examination of the skin lesions showed mono nuclear cell infiltration, mast cell hyperplasia, and dermal fibrosis.

    A chronic (26-week) drinking water exposure study in NZB × NZW mice reported an increased level of proteinuria and prevalence of renal pathology, but no evidence of liver disease, with a TCE exposure of 10,000 ppb in drinking water (Gilkeson et al. 2004) (Table 1). Production of anti–double-stranded DNA (anti-dsDNA) and other antibodies was increased at 1,400 ppb TCE (but not 14,000 ppb) at 19 weeks; the differences lessened from 23 to 30 weeks and then increased between 32 and 34 weeks.

    In a study in the male MRL-lpr/lpr mouse, Kaneko et al. (2000) exposed the mice via inhalation for 8 weeks to 0, 500, 1,000, or 2,000 ppm TCE (4 hr/day, 6 days/week). IgG and IgM levels were reduced, but IgA levels and levels of T-helper and T-suppressor cells did not differ across exposures over the course of the study. The authors also found histologic changes in the liver and spleen, but not in the thymus, in the highest dose group (Table 1).

    In vitro and mechanistic studies

    Initial studies of TCE exposure in MRL+/+ mice noted the activation of a specific immune serum antibody response directed against dichloroacetylated proteins (Gilbert et al. 1999; Griffin et al. 2000a; Khan et al. 1995). Immunohistochemical staining also revealed TCE-modified protein adducts in the liver and lung (Gilbert et al. 1999; Griffin et al. 2000a). Cai et al. (2007) extended these observations using an experiment involving immunization of various albumin adducts (trichloroethene oxide, dichloroacyl, formyl, and trifluroacyl) injected subcutaneously for 0, 2, or 4 weeks in groups of five female MRL+/+ mice. The authors used trifluroacyl albumin adduct as a positive control based on its role in halothane autoimmune liver disease. The immunogenicity of the protein adducts was demonstrated by the increased albumin-specific IgG seen in all albumin-adduct–treated groups. Cross-reactivity between adducts was also evident. Although Cai et al. (2007) found no differences in serum liver enzymes (alanine aminotransferase and aspartate aminotransferase), the formyl-albumin immunization resulted in a hepatic lymphocyte infiltration. These results suggest that the production of formyl-haptenized proteins from TCE may be a key factor in the development of the effects seen in the MRL+/+ mouse studies.

    A series of experiments examined the role for oxidative stress, and specifically of lipid-peroxidation-derived aldehydes, in TCE-induced autoimmune disease. The hypothesized mechanism involves the binding of these reactive aldehydes to proteins to form neoantigen targets for autoantibody formation. Wang et al. (2007a) detected malondialdehyde and 4-hydroxynonenal protein adducts (reflecting lipid peroxidation) in the livers of female MRL+/+ mice treated for 6 and 12 weeks with 10 mmol/kg TCE (every fourth day, by ip injection). The same group found antimalondialdehyde anti bodies and antihydroxynonenal antibodies with 4- to 12-week ip exposure to TCE (Khan et al. 2001; Wang et al. 2007a, 2007b, 2008) and 48-week oral exposure to TCE (Wang et al. 2007b) or dichloroacetyl chloride (Khan et al. 2001). These antibodies were correlated with ANA (Wang et al. 2007a, 2007b). Wang et al. (2008) found proliferation and activation of splenic CD4+ T cells after stimulation with malondialdehyde-adducted or 4-hydroxy-nonenal–adducted mouse serum albumin.

    Other studies have examined potential mechanisms through which TCE-related compounds affect T-cell stimulation and apoptosis. In a short-term (4-week) exposure study, Blossom et al. (2004) found a dose-related inhibition of anti-CD3–mediated (activation-induced) apoptosis of CD4+ T cells with oral exposures to 0, 0.1, and 0.9 mg/mL trichloroacetaldehyde hydrate. With a longer exposure period (40 weeks), however, they found no effect on anti-CD3–mediated apoptosis of CD4+ T cells and no difference in expression of Fas or Fas ligand (Blossom et al. 2007). This difference paralleled a difference in metalloproteinase-7 levels, which were elevated at 4 weeks but not at 40 weeks (Blossom et al. 2007; Blossom and Gilbert 2006).

    Other rodent models

    The Brown Norway rat has been used as a model of chemical-induced complex-mediated glomerulonephritis, for example, in studies of mercuric chloride (Sapin et al. 1977). The disease is complex-mediated, similar to that seen in humans with systemic lupus erythematosus. Polyclonal stimulation and increased IgE levels are hallmarks of the disease in the Brown Norway rat. White et al. (2000) administered TCE by gavage to female Brown Norway rats for 6 weeks (100, 200, or 400 mg/kg, 6–8 animals per dose) and found no increase in IgE compared with the vehicle controls.

    In the study of NZB × NZW mice described above, Gilkeson et al. (2004) also included a parallel study of B6C3F1 mice, a model that typically does not develop auto-immune sequelae. Increases in anti-dsDNA antibodies were statistically significant or of borderline significance (p = 0.07) at all times after 26 weeks exposure to 1,400 ppb or 14,000 ppb TCE via drinking water.

    Epidemiologic Studies

    Measures of immune function and markers

    The available data from studies in humans also provide evidence of an association between increased TCE exposure and cytokine measures indicative of an inflammatory immune response (Table 2). Iavicoli et al. (2005) examined cytokine levels in 35 male TCE-exposed workers (degreasers) from a printing area of a factory in Italy and compared these workers with two control groups: other male factory workers not involved in degreasing activities (n = 30) and male office workers at the factory (n = 40). The mean TCE concentration among exposed workers was approximately 35 mg/m3. The authors observed no difference in serum cytokine concentrations (measured using enzyme-linked immunosorbent assays) between the two control groups, but they found considerable differences in the exposed group compared with the nonexposed workers (for all, p < 0.01): exposed workers had lower IL-4 levels and higher IL-2 and IFN-γ levels (Table 2).

    Table 2 Studies of cytokines and TCE exposure in humans.

    Reference, location, no., and ageSource of exposure data, outcome measuresResults
    Iavicoli et al. 2005 Italy; 35 exposed workers, 30 nonexposed workers, and 40 office worker controls, all male; mean age ~ 33 yearsUrine sample (for trichloroacetic acid concentration); workplace TCE measures (personal samples, 4 exposed and 4 nonexposed workers); questionnaire (smoking history, age, residence); serum cytokine levelsNonexposed workers similar to office controls for all cytokine measures; compared with nonexposed workers, TCE-exposed workers had decreased IL-4 (mean, 3.9 vs. 8.1 pg/mL), increased IL-2 (mean, 798 vs. 706 pg/mL), and increased IFN-γ (mean, 37.1 vs. 22.9 pg/mL)
    Lehmann et al. 2001 Germany; 28 children, 36 months of ageIndoor air sampling (child’s bedroom) of 28 volatile organic chemicals; cytokine-secreting CD3+ and CD8+ T cell populations from blood sampleTCE exposure not associated with percentages of IL-4 CD3+ or IFN-γ CD8+ T-cells
    Lehmann et al. 2002 Germany; 85 newbornsIndoor air sampling (child’s bedroom) of 28 volatile organic chemicals (4 weeks after birth); cytokine-secreting CD3+ T cell populations from CD3+ cord blood cellsIncreasing TCE levels associated with decreased IL-4 (OR = 4.4; 95% CI, 1.1–17.8) for < 25th percentile IL-4 and increased IFN-γ (OR = 3.6; 95% CI, 0.9–14.9) for > 75th percentile IFN-γ; no association with TNF-α or IL-2

    Two other studies measured the percentage of cytokine-secreting CD3+ (or CD3+ and CD8+) T cells in relation to measures of TCE exposure from indoor air samples. Lehmann et al. (2001) found no association in the pilot study conducted with 28 children 36 months of age, but a larger study of 85 infants (4 weeks of age) reported a decrease in the population of IL-4–secreting cells and an increase in IFN-γ–secreting cells in relation to higher exposure to TCE (defined as > 75th percentile of the distribution) (Lehmann et al. 2002).

    Byers et al. (1988) collected serum samples from 23 family members of leukemia patients in Woburn. They used these samples to assess the presence of autoantibodies (ANA, anti-smooth muscle, anti ovarian, anti thyroglobulin, and antimicrosomal antibodies) in the family member samples and compared the results with laboratory reference values. None of the serum samples from family member contained antithyroglobulin or antimicrosomal antibodies, but ANA were detected in samples from 10 (43%) family members (compared with < 5% expected based on the reference value).

    The aquifer of the Santa Cruz River in Tucson, Arizona, had been contaminated with solvents (primarily TCE) and heavy metals (e.g., chromium). Kilburn and Warshaw (1992, 1993) examined the prevalence of connective tissue disease symptoms and ANA, comparing 362 residents of Tucson to 158 residents of another area of southwest Arizona. They selected the Tucson residents from the neighborhoods with documented water contamination (> 5 ppb TCE for at least 1 year between 1957 and 1981). The recruitment process was not described clearly, but in Tucson it seems to have specifically involved patients with lupus or other rheumatic diseases (Kilburn and Warshaw 1992, 1993). In contrast, they recruited the comparison group through a Catholic parish. The prevalence of some self-reported symptoms (malar rash, arthritis/arthalgias, Raynaud syndrome, skin lesions, and seizure or convulsion) and of low-titer (1:80) ANA was higher in Tucson (Kilburn and Warshaw 1992). It is difficult to attribute these differences to the water supply, however, given the process that went into participant recruitment (with part of the Tucson group selected based on the presence of rheumatic diseases) and the lack of verification of the self-reported symptoms.

    Systemic autoimmune diseases

    Interest in the role of chlorinated compounds in auto-immune diseases was spurred by the observation of a scleroderma-like disease in workers exposed to vinyl chloride (Gama and Meira 1978), and several case reports focused on TCE (Flindt-Hansen and Isager 1987; Lockey et al. 1987; Saihan et al. 1978). Larger epidemiologic studies (case–control or population-registry–based designs) using broad measures of occupational exposure to solvents, organic solvents, or chlorinated solvents generally reported a 2- to 3-fold increased risk of systemic sclerosis (scleroderma) (Aryal et al. 2001; Garabrant et al. 2003; Maitre et al. 2004), rheumatoid arthritis (Lundberg et al. 1994; Sverdrup et al. 2005), undifferentiated connective tissue disease (Lacey et al. 1999), and anti-neutrophil-cytoplasmic antibody (ANCA)–related vasculitis (Beaudreuil et al. 2005; Lane et al. 2003), but similar associations have not been found in studies of lupus (Cooper et al. 2004; Finckh et al. 2006).

    Two case–control studies of scleroderma (Bovenzi et al. 2004; Maitre et al. 2004) and two of rheumatoid arthritis (Olsson et al. 2000, 2004) provided data concerning solvent exposure that occurred among metal workers or in jobs that involved cleaning metal (i.e., types of jobs that were likely to use TCE as a solvent). Olsson et al. (2000, 2004) found a 2-fold increased risk among male workers in studies of rheumatoid arthritis from Sweden. The results from the smaller studies of scleroderma were more variable: Maitre et al. (2004) found no exposed cases in a study with 93 cases and 206 controls, and Bovenzi et al. (2004) found an odds ratio (OR) of 5.2 [95% confidence interval (CI), 0.7–37] in a study with 56 cases and 171 controls.

    Five other case–control studies provided data specifically about TCE exposure, based on industrial hygienist review of job history data (Table 3). Three of these studies are of scleroderma (Diot et al. 2002; Garabrant et al. 2003; Nietert et al. 1998), one is of undifferentiated connective tissue disease (Lacey et al. 1999), and one is of small vessel vasculitis involving ANCA (Beaudreuil et al. 2005). These studies included some kind of expert review of job histories, but only two studies included a characterization of exposure level (e.g., a cumulative exposure metric) or a “high” exposure group (Diot et al. 2002; Nietert et al. 1998). Most of the studies presented data stratified by sex. The test for heterogeneity between results for males and those for females just missed statistical significance (p = 0.058). We decided that performing separate analyses for these groups was warranted because the substantial gender-related differences in the background rate of scleroderma and in the prevalence of TCE exposure provide additional rationale for examining gender-related differences in measures of association. In men, the studies generally reported ORs between 2.0 and 8.0, and in women, the ORs were between 1.0 and 2.0. The meta-analysis of scleroderma studies with TCE exposure data (Diot et al. 2002; Garabrant et al. 2003; Nietert et al. 1998) resulted in a combined OR for “any” exposure of 2.5 (95% CI, 1.1–5.4) for men and 1.2 (95% CI, 0.58–2.6) for women (Figure 1). There was no clear support for heterogeneity within the male and female subgroupings (p = 0.35 for men and 0.16 for women).

    Figure 1 Association between risk of scleroderma and occupational exposure to TCE in men (A) and women (B), based on data from three case–control studies (Diot et al. 2002; Garabrant et al. 2003; Nietert et al. 1998). The graphics show the estimated measures of association from these studies. The pooled estimates are based on a meta-analysis using a random-effects model to include the possibility of nonrandom error between studies. Each square and corresponding line represent the OR and 95% CI from the individual study, with the relative size of the squares reflecting the relative weights of the studies. The horizontal midpoint of each diamond represents the pooled OR estimate and the horizontal extremes indicate the 95% CI.

    Table 3 Epidemiologic studies of TCE exposure and risk of scleroderma and other autoimmune diseases.

    Disease, reference, location, period, sample size, ageSource of exposure dataExposure definition/prevalence
    Source of exposure dataCohortCases (%)Controls (%)OR (95% CI)
    Scleroderma (systemic sclerosis)

    Nietert et al. 1998 South Carolina; prevalent cases, 1995–1997; 178 cases (141 women, 37 men), 200 hospital-based controls; mean age at onset, 45.2 yearsStructured interview (specific jobs and materials; jobs held ≥ 1 year); classified by expert review (job exposure matrix)Men
     Any exposurea51422.0 (0.8–4.9)
     Maximum intensity30103.3 (1.0–10.3)
     Cumulative intensity32212.0 (0.7–5.3)
     Maximum probability1635.1 (NC)
     Any exposurea19240.7 (0.4–1.3)
     Maximum intensity670.9 (0.3–2.3)
     Cumulative intensity1091.2 (0.5–2.6)
     Maximum probability450.7 (0.2–2.2)
    Diot et al. 2002 France; prevalent cases hospitalized 1998–2000; 80 cases (69 women, 11 men), 160 hospital controls; mean age at diagnosis, 48 yearsStructured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert reviewMen and women
     Any exposure1682.4 (1.0–5.2)
     High exposureb917.6 (1.5–37.4)
     Any exposure64274.7 (0.99–21.9)
     Any exposure942.1 (0.65–6.8)
    Garabrant et al. 2003 Michigan and Ohio; prevalent cases diagnosed 1980–1992; 660 cases (all women), 2,227 population controls;c ages, ≥ 18 yearsStructured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and expert reviewWomen
     Self-report, any exposure1.30.72.0 (0.8–4.8)
     Expert review, any exposure0.70.41.9 (0.6–6.6)

    Undifferentiated connective tissue disease

    Lacey et al. 1999 Michigan and Ohio; prevalent cases diagnosed 1980–1991 (Michigan), 1980–1992 (Ohio); 205 cases (all women), 2,095 population controls; ages, ≥ 18 yearsStructured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and by expert reviewWomen
     Self-report, any exposure0.50.70.88 (0.11–6.95)
     Expert review, any exposure0.50.41.67 (0.19–14.9)

    ANCA-related diseasesd

    Beaudreuil et al. 2005 France; incident cases diagnosed 1999–2000; 60 cases (~ 50% women), 120 hospital controls; mean age, 61 yearsStructured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert reviewMen and women
     Any exposure18.317.51.1 (0.5 – 2.4)
     Data not presented separately by sex

    NC, not calculated.

    aThe publication did not include “any” exposure, but this was generated by the original author (P. Nietert) as part of the present analysis.

    bProduct of probability × intensity × frequency × duration scores, summed across all jobs; scores of > 1 classified as “high.”

    cTotal number with TCE data: self-report 606 cases, 2,138 control; expert review 606 cases, 2,137 controls.

    dDiseases included Wegener glomerulonephritis (n = 20), microscopic polyangiitis (n = 8), pauci-immune glomerulonephritis (n = 10), uveitis (n = 6), Churg-Strauss syndrome (n = 4), stroke (n = 4), and other diseases (≤ 2 each).


    During the past decade there has been considerable research, in experimental animals and in humans, pertaining to immune-related effects of TCE. Data concerning immunosuppression, particularly in humans, are still somewhat limited. In contrast, a fuller picture is shown by the studies of hypersensitivity, dermatitis, and hepatic injury, an emerging occupational concern in China and other industrializing areas.

    The autoimmune-related studies, many of which were conducted in the past 5 years, represent a broad and robust literature, exhibiting many of the attributes that lend support for a causal relation between exposure and disease, including strength, consistency, dose–response patterns, and biological plausibility (Hill 1965; Legator and Morris 2003). Autoimmune mouse strains with a relatively less severe lupus phenotype (i.e., delayed disease onset), such as seen in the MRL+/+ mouse, provide an experimental model to examine the acceleration of lupus pathology. Numerous studies using different routes of exposure and dose ranges have demonstrated an accelerated autoimmune response in MRL+/+ mice. In the oral exposure studies, the duration of exposure period clearly influences the observed effects, with the acceleration (as measured by auto-antibody production, T-cell activation, and inflammatory cytokine secretion or serum levels) generally seen with shorter exposures (Blossom et al. 2004; Griffin et al. 2000a, 2000b), and clinical effects seen with longer exposure periods (Blossom et al. 2007; Cai et al. 2008; Gilkeson et al. 2004; Griffin et al. 2000b). The different effects seen with short compared with long exposure durations in the MRL+/+ mouse experiments may reflect the varying disease course and varying response in specific target tissues during different phases of pathogenesis (Greidinger et al. 2007). It is interesting that the clinical effects seen in the MRL+/+ mouse chronic exposure studies (36–48 weeks) (Blossom et al. 2007; Cai et al. 2008; Griffin et al. 2000b) differ somewhat from “normal” expression within these mice. That is, the effects seen included an inflammatory hepatic infiltrate, diffuse alopecia, and skin inflammation and ulceration.

    Studies using autoimmune mouse strains also provide a means to examine potential mechanisms of action as well as the effects of various doses and durations of exposure. The formation of immunogenic TCE-induced adducts of liver proteins and lipid-peroxidation–derived aldehydes and potential role of oxidative stress in promoting an aberrant autoimmune response to neoantigens in the liver and other tissues are some of the mechanistic hypotheses that have been raised by this research.

    Data from experimental studies in non-lupus-prone animals are limited. In a study in the Brown Norway rat, White et al. (2000) found no increase in IgE with gavage doses of up to 400 mg/kg-day for 6 weeks, but Gilkeson et al. (2004) found increases in anti-dsDNA antibodies in B6C3F1 mice after 26 weeks of exposure to 1,400 ppb or 14,000 ppb via drinking water.

    Are the effects seen in the MRL+/+ mouse also seen in humans? Occupational studies have examined inflammatory cytokines and specific systemic autoimmune diseases, although our literature search did not find any studies of TCE exposure and either lupus or autoimmune liver disease. We found no cohort studies of the incidence of auto immune diseases in workers exposed to TCE, but the available case–control studies of scleroderma and TCE support the relevance of this disease within the context of human exposures. Although the association is generally stronger in studies in men compared with those in women, it is not clear whether this difference reflects the relatively low background risk of scleroderma in men, differences in exposure prevalence or in the reliability of exposure assessment (Messing et al. 2003), or a gender-related difference in susceptibility to the effects of TCE. Given the available studies in scleroderma and more limited data in other systemic autoimmune diseases, it is difficult to argue that the investigations into disease acceleration and variations in manifestations of effect seen in lupus-prone mice are irrelevant to humans. The variation in clinical expression of disease in response to TCE exposure remains an important research question to be addressed by both mechanistic and epidemiologic studies.

    Systemic sclerosis (scleroderma) and autoimmune liver disease are relatively rare in humans, with incidence rates of about 1/100,000 per year; incidence rates for systemic lupus erythematosus are somewhat higher (5–10 per 100,000 per year) (Cooper and Stroehla 2003) but still low enough to present considerable challenges to performing adequately powered epidemiologic studies. An additional impediment to autoimmune disease research is the lack of disease registries, which adds to the difficulty in identifying incident cases of specific diseases. The insights generated by the recent experimental studies of TCE, however, provide a strong rationale for developing the type of multi site collaborations needed to address the potential influence of TCE or other solvents operating through a similar pathway on the incidence of specific autoimmune diseases, and for evaluating the potential immune-related effects of low-level exposures from environmental contamination. Development and validation of exposure assessment techniques incorporating occupational and environmental exposure pathways, use of quantitative exposure metrics, examination of multiple solvents and other agents, and studies of markers of immune function expressed before onset of disease would be instrumental in the further advancement of these efforts.

    The views expressed are those of the authors and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency.


    • Aranyi C, O’Shea WJ, Graham JA, Miller FJ. 1986. The effects of inhalation of organic chemical air contaminants on murine lung host defenses. Fundam Appl Toxicol 6:713-7203519345. Crossref, MedlineGoogle Scholar
    • Aryal BK, Khuder SA, Schaub EA. 2001. Meta-analysis of systemic sclerosis and exposure to solvents. Am J Ind Med 40:271-27411598973. Crossref, MedlineGoogle Scholar
    • Beaudreuil S, Lasfargues G, Laueriere L, El Ghoul Z, Fourquet F, Longuet Cet al.. 2005. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 67:1961-196615840044. Crossref, MedlineGoogle Scholar
    • Blossom SJ, Doss JC, Gilbert KM. 2007. Chronic exposure to a trichloroethylene metabolite in autoimmune-prone MRL+/+ mice promotes immune modulation and alopecia. Toxicol Sci 95:401-41117077186. Crossref, MedlineGoogle Scholar
    • Blossom SJ, Gilbert KM. 2006. Exposure to a metabolite of the environmental toxicant, trichloroethylene, attenuates CD4+ T cell activation-induced cell death by metalloproteinase-dependent FasL shedding. Toxicol Sci 92:103-11416641322. Crossref, MedlineGoogle Scholar
    • Blossom SJ, Pumford NR, Gilbert KM. 2004. Activation and attenuation of apoptosis of CD4+ T cells following in vivo exposure to two common environmental toxicants, trichloroacetaldehyde hydrate and trichloroacetic acid. J Autoimmun 23:211-22015501392. Crossref, MedlineGoogle Scholar
    • Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello Aet al.. 2004. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 77:10-1614530983. Crossref, MedlineGoogle Scholar
    • Byers VS, Levin AS, Ozonoff DM, Baldwin RW. 1988. Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated domestic water supply and a high incidence of leukaemia. Cancer Immunol Immunother 27:77-813260823. Crossref, MedlineGoogle Scholar
    • Cai P, Konig R, Boor PJ, Kondraganti S, Kaphalia BS, Khan MFet al.. 2008. Chronic exposure to trichloroethene causes early onset of SLE-like disease in female MRL+/+ mice. Toxicol Appl Pharmacol 228:68-7518234256. Crossref, MedlineGoogle Scholar
    • Cai P, Konig R, Khan MF, Kaphalia BS, Ansari GA. 2007. Differential immune responses to albumin adducts of reactive intermediates of trichloroethene in MRL+/+ mice. Toxicol Appl Pharmacol 220:278-28317376499. Crossref, MedlineGoogle Scholar
    • Cai P, Konig R, Khan MF, Qiu S, Kaphalia BS, Ansari GA. 2006. Autoimmune response in MRL+/+ mice following treatment with dichloroacetyl chloride or dichloroacetic anhydride. Toxicol Appl Pharmacol 216:248-25516806339. Crossref, MedlineGoogle Scholar
    • Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Dooley MA. 2004. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol 31:1928-193315468355. MedlineGoogle Scholar
    • Cooper GS, Stroehla BC. 2003. The epidemiology of auto immune diseases. Autoimmun Rev 2:119-12512848952. Crossref, MedlineGoogle Scholar
    • DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177-1883802833. Crossref, MedlineGoogle Scholar
    • Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier Set al.. 2002. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 59:545-54912151611. Crossref, MedlineGoogle Scholar
    • Finckh A, Cooper GS, Chibnik LB, Costenbader KH, Watts J, Pankey Het al.. 2006. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 54:3648-365417075811. Crossref, MedlineGoogle Scholar
    • Flindt-Hansen H, Isager H. 1987. Scleroderma after occupational exposure to trichlorethylene and trichlorethane. Acta Derm Venereol 67:263-2642442944. MedlineGoogle Scholar
    • Gama C, Meira JB. 1978. Occupational acro-osteolysis. J Bone Joint Surg Am 60:86-90624763. Crossref, MedlineGoogle Scholar
    • Garabrant DH, Lacey JV, Laing TJ, Gillespie BW, Mayes MD, Cooper BCet al.. 2003. Scleroderma and solvent exposure among women. Am J Epidemiol 157:493-50012631538. Crossref, MedlineGoogle Scholar
    • Gilbert KM, Griffin JM, Pumford NR. 1999. Trichloroethylene activates CD4+ T cells: potential role in an autoimmune response. Drug Metab Rev 31:901-91610575554. Crossref, MedlineGoogle Scholar
    • Gilkeson GS, Keil D, Peden-Adams MM, Mohr LC, Hoel DG, Jollow D. 2004. Immune effects of trichloroethylene on autoimmune disease in mice. Trichloroethylene: The Scientific Basis of Risk AssessmentCharleston, SCMedical University of South Carolina87-98. Google Scholar
    • Greidinger EL, Zang Y, Martinez L, Jaimes K, Nassiri M, Bejarano Pet al.. 2007. Differential tissue targeting of auto-immunity manifestations by autoantigen-associated Y RNAs. Arthritis Rheum 56:1589-159717469141. Crossref, MedlineGoogle Scholar
    • Griffin JM, Blossom SJ, Jackson SK, Gilbert KM, Pumford NR. 2000a. Trichloroethylene accelerates an autoimmune response by Th1 T cell activation in MRL+/+ mice. Immuno-pharmacology 46:123-137. Crossref, MedlineGoogle Scholar
    • Griffin JM, Gilbert KM, Lamps LW, Pumford NR. 2000b. CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL+/+ mice. Toxicol Sci 57:345-35211006364. Crossref, MedlineGoogle Scholar
    • Griffin JM, Gilbert KM, Pumford NR. 2000c. Inhibition of CYP2E1 reverses CD4+ T-cell alterations in trichloroethylene-treated MRL+/+ mice. Toxicol Sci 54:384-38910774820. Crossref, MedlineGoogle Scholar
    • Hill AB. 1965. The environment and disease: association or causation?Proc R Soc Med 58:295-30014283879. MedlineGoogle Scholar
    • Huang HL, Li LY, Chen B, Huang JX, Huang SR. 2002. New problems caused by occupational trichlorethylene exposure. Int J Immunopathol Pharmacol 15:30-32. Google Scholar
    • Iavicoli I, Marinaccio A, Carelli G. 2005. Effects of occupational trichloroethylene exposure on cytokine levels in workers. J Occup Environ Med 47:453-45715891523. Crossref, MedlineGoogle Scholar
    • Kamijima M, Hisanaga N, Wang H, Nakajima T. 2007. Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities. Int Arch Occup Environ Health 80:357-37017106739. Crossref, MedlineGoogle Scholar
    • Kamijima M, Wang H, Huang H, Li L, Shibata E, Lin Bet al.. 2008. Trichloroethylene causes generalized hypersensitivity skin disorders complicated by hepatitis. J Occup Health 50:328-33818540116. Crossref, MedlineGoogle Scholar
    • Kaneko T, Saegusa M, Tasaka K, Sato A. 2000. Immunotoxicity of trichloroethylene: a study with MRL-lpr/lpr mice. J Appl Toxicol 20:471-47511180269. Crossref, MedlineGoogle Scholar
    • Kauffmann BM, White KL, Sanders VM, Douglas KA, Sain LE, Borzelleca JFet al.. 1982. Humoral and cell-mediated immune status in mice exposed to chloral hydrate. Environ Health Perspect 44:147-1516979478. LinkGoogle Scholar
    • Khan MF, Kaphalia BS, Prabhakar BS, Kanz MF, Ansari GA. 1995. Trichloroethene-induced autoimmune response in female MRL+/+ mice. Toxicol Appl Pharmacol 134:155-1607676450. Crossref, MedlineGoogle Scholar
    • Khan MF, Wu X, Ansari GA. 2001. Anti-malondialdehyde antibodies in MRL+/+ mice treated with trichloroethene and dichloroacetyl chloride: possible role of lipid peroxidation in autoimmunity. Toxicol Appl Pharmacol 170:88-9211162772. Crossref, MedlineGoogle Scholar
    • Kilburn KH, Warshaw RH. 1992. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res 57:1-91740091. Crossref, MedlineGoogle Scholar
    • Kilburn KH, Warshaw RH. 1993. Neurobehavioral testing of subjects exposed residentially to groundwater contaminated from an aluminum die-casting plant and local referents. J Toxicol Environ Health 39:483-4968345533. Crossref, MedlineGoogle Scholar
    • Lacey JV, Garabrant DH, Laing TJ, Gillespie BW, Mayes MD, Cooper BCet al.. 1999. Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). Am J Epidemiol 149:761-77010206626. Crossref, MedlineGoogle Scholar
    • Lagakos SW, Wessen BJ, Zelen M. 1986. An analysis of contaminated well water and health effects in Woburn, Massachusetts. J Am Stat Assoc 81:583-596. CrossrefGoogle Scholar
    • Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. 2003. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 48:814-82312632437. Crossref, MedlineGoogle Scholar
    • Lash LH, Fisher JW, Lipscomb JC, Parker JC. 2000. Metabolism of trichloroethylene. Environ Health Perspect 108(suppl 2):177-20010807551. LinkGoogle Scholar
    • Legator MS, Morris DL. 2003. What did Sir Bradford Hill really say?Arch Environ Health 58:718-72015702898. MedlineGoogle Scholar
    • Lehmann I, Rehwagen M, Diez U, Seiffart A, Rolle-Kampczyk U, Richter Met al.. 2001. Enhanced in vivo IgE production and T cell polarization toward the type 2 phenotype in association with indoor exposure to VOC: results of the LARS study. Int J Hyg Environ Health 204:211-22111833293. Crossref, MedlineGoogle Scholar
    • Lehmann I, Thoelke A, Rehwagen M, Rolle-Kampczyk U, Schlink U, Schulz Ret al.. 2002. The influence of maternal exposure to volatile organic compounds on the cytokine secretion profile of neonatal T cells. Environ Toxicol 17:203-21012112628. Crossref, MedlineGoogle Scholar
    • Lockey JE, Kelly CR, Cannon GW, Colby TV, Aldrich V, Livingston GK. 1987. Progressive systemic sclerosis associated with exposure to trichloroethylene. J Occup Med 29:493-4963612322. MedlineGoogle Scholar
    • Lundberg I, Alfredsson L, Plato N, Sverdrup B, Klareskog L, Kleinau S. 1994. Occupation, occupational exposure to chemicals and rheumatological disease. A register based cohort study. Scand J Rheumatol 23:305-3107801054. Crossref, MedlineGoogle Scholar
    • Maitre A, Hours M, Bonneterre V, Arnaud J, Arslan MT, Carpentier Pet al.. 2004. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 31:2395-240115570640. MedlineGoogle Scholar
    • Messing K, Punnett L, Bond M, Alexanderson K, Pyle J, Zahm Set al.. 2003. Be the fairest of them all: challenges and recommendations for the treatment of gender in occupational health research. Am J Ind Med 43:618-62912768612. Crossref, MedlineGoogle Scholar
    • National Center for Biotechnology Information. 2008. PubMedAvailable:[accessed 16 October 2008]. Google Scholar
    • National Research Council. 2006. Assessing the Human Health Risks of Trichloroethylene: Key Scientific IssuesWashington, DCThe National Academies Press. Google Scholar
    • Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Knapp RG, Hoel DGet al.. 1998. Is occupational organic solvent exposure a risk factor for scleroderma?Arthritis Rheum 41:1111-11189627022. Crossref, MedlineGoogle Scholar
    • Olsson AR, Skogh T, Axelson O, Wingren G. 2004. Occupations and exposures in the work environment as determinants for rheumatoid arthritis. Occup Environ Med 61:233-23814985518. Crossref, MedlineGoogle Scholar
    • Olsson AR, Skogh T, Wingren G. 2000. Occupational determinants for rheumatoid arthritis. Scand J Work Environ Health 26:243-24910901117. Crossref, MedlineGoogle Scholar
    • Peden-Adams MM, Eudaly JG, Heesemann LM, Smythe J, Miller J, Gilkeson GSet al.. 2006. Developmental immunotoxicity of trichloroethylene (TCE): studies in B6C3F1 mice. J Environ Sci Health A Toxicol Hazard Subst Environ Eng 41:249-271. Crossref, MedlineGoogle Scholar
    • Peden-Adams MM, Eudaly JG, Lee AM, Miller J, Keil DE, Gilkeson GS. 2008. Lifetime exposure to trichloroethylene (TCE) does not accelerate autoimmune disease in MRL +/+ mice. J Environ Sci Health A Toxicol Hazard Subst Environ Eng 43:1402-1409. Crossref, MedlineGoogle Scholar
    • Saihan EM, Burton JL, Heaton KW. 1978. A new syndrome with pigmentation, scleroderma, gynaecomastia, Raynaud’s phenomenon and peripheral neuropathy. Br J Dermatol 99:437-440213095. Crossref, MedlineGoogle Scholar
    • Sanders VM, Tucker AN, White KL, Kauffmann BM, Hallett P, Carchman RAet al.. 1982. Humoral and cell-mediated immune status in mice exposed to trichloroethylene in the drinking water. Toxicol Appl Pharmacol 62:358-3687071855. Crossref, MedlineGoogle Scholar
    • Sapin C, Druet E, Druet P. 1977. Induction of anti-glomerular basement membrane antibodies in the Brown-Norway rat by mercuric chloride. Clin Exp Immunol 28:173-179324675. MedlineGoogle Scholar
    • Sverdrup B, Kallberg H, Bengtsson C, Lundberg I, Padyukov L, Alfredsson Let al.. 2005. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res Ther 7:R1296-R130316277683. Crossref, MedlineGoogle Scholar
    • Tang X, Que B, Song X, Li S, Yang X, Wang Het al.. 2008. Characterization of liver injury associated with hypersensitive skin reactions induced by trichloroethylene in the guinea pig maximization test. J Occup Health 50:114-12118403861. Crossref, MedlineGoogle Scholar
    • Tang XJ, Li LY, Huang JX, Deng YY. 2002. Guinea pig maximization test for trichloroethylene and its metabolites. Biomed Environ Sci 15:113-11812244752. MedlineGoogle Scholar
    • Wang G, Ansari GA, Khan MF. 2007a. Involvement of lipid peroxidation-derived aldehyde-protein adducts in auto-immunity mediated by trichloroethene. J Toxicol Environ Health A 70:1977-198517966069. Crossref, MedlineGoogle Scholar
    • Wang G, Cai P, Ansari GA, Khan MF. 2007b. Oxidative and nitrosative stress in trichloroethene-mediated auto immune response. Toxicology 229:186-19317123686. Crossref, MedlineGoogle Scholar
    • Wang G, Konig R, Ansari GA, Khan MF. 2008. Lipid peroxidation-derived aldehyde-protein adducts contribute to trichloroethene-mediated autoimmunity via activation of CD4+ T cells. Free Radic Biol Med 44:1475-148218267128. Crossref, MedlineGoogle Scholar
    • White KL, David DW, Butterworth LF, Klykken PC. 2000. Assessment of autoimmunity-inducing potential using the Brown Norway rat challenge model. Toxicol Lett 112-113443-451. Google Scholar
    • Wright PF, Thomas WD, Stacey NH. 1991. Effects of trichloroethylene on hepatic and splenic lymphocytotoxic activities in rodents. Toxicology 70:231-2421763417. Crossref, MedlineGoogle Scholar